Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ecancermedicalscience
Main Authors: Cocorocchio, E, Gandini, S, Alfieri, S, Battaglia, A, Pennacchioli, E, Tosti, G, Spadola, G, Barberis, M, Leo, M Di, Riviello, C, Pala, L, Intelisano, A, Martinoli, C, Ferrucci, PF
Format: Artigo
Sprog:Inglês
Udgivet: Cancer Intelligence 2016
Fag:
Clinical Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778691/
https://ncbi.nlm.nih.gov/pubmed/26981153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2016.624
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker